Redx Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Redx Pharma şirketinin gelirinin ve kazancının sırasıyla yıllık 37.6% ve 22.3% oranında düşmesi öngörülüyor.

Anahtar bilgiler

-22.3%

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	21.5%
Gelir büyüme oranı	-37.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	02 Apr 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:0RX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2025	N/A	-49	N/A	-48	1
9/30/2024	13	-26	N/A	-24	1
9/30/2023	4	-33	-35	-35	N/A
6/30/2023	8	-31	-32	-32	N/A
3/31/2023	13	-29	-30	-30	N/A
12/31/2022	16	-24	-19	-19	N/A
9/30/2022	19	-18	-9	-8	N/A
6/30/2022	17	-18	-8	-8	N/A
3/31/2022	16	-19	-8	-7	N/A
12/31/2021	13	-20	-15	-14	N/A
9/30/2021	10	-22	-22	-21	N/A
6/30/2021	8	-20	-15	-14	N/A
3/31/2021	7	-18	-7	-7	N/A
12/31/2020	6	-14	-4	-3	N/A
9/30/2020	6	-9	0	0	N/A
6/30/2020	5	-8	-2	-2	N/A
3/31/2020	4	-6	-5	-5	N/A
12/31/2019	4	-5	-5	-5	N/A
9/30/2019	3	-4	-5	-5	N/A
6/30/2019	2	-5	-6	-6	N/A
3/31/2019	N/A	-7	-8	-8	N/A
12/31/2018	0	-8	-13	-13	N/A
9/30/2018	0	-9	-17	-17	N/A
6/30/2018	15	-1	-4	-4	N/A
3/31/2018	31	8	9	9	N/A
12/31/2017	31	5	11	11	N/A
9/30/2017	30	2	14	14	N/A
6/30/2017	15	-9	N/A	-1	N/A
3/31/2017	N/A	-19	N/A	-16	N/A
12/31/2016	N/A	-17	N/A	-14	N/A
9/30/2016	N/A	-16	N/A	-13	N/A
6/30/2016	N/A	-14	N/A	-11	N/A
3/31/2016	N/A	-12	N/A	-9	N/A
12/31/2015	N/A	-10	N/A	-8	N/A
9/30/2015	N/A	-8	N/A	-7	N/A
6/30/2015	N/A	-7	N/A	-6	N/A
3/31/2015	N/A	-5	N/A	-5	N/A
12/31/2014	N/A	-4	N/A	-4	N/A
9/30/2014	N/A	-3	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0RX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 0RX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 0RX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 0RX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -37.6% ).

Yüksek Büyüme Geliri: 0RX şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -37.6% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0RX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Redx Pharma Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Redx Pharma Plc Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress

Redx to Present Zamaporvint Phase2 Data At Esmo Gi

Redx to Present Preclinical Data on RXC008 in an Oral Presentation at ECM Congress

Redx Pharma Provides Update on AIM Delisting

Redx Announces That First Participant Dosed in Phase 1 Trial of RXC008

Full year 2023 earnings released: UK£0.099 loss per share (vs UK£0.061 loss in FY 2022)

Redx Pharma Plc, Annual General Meeting, Mar 14, 2024

New minor risk - Share price stability

New minor risk - Market cap size

Full year 2023 earnings released: UK£0.099 loss per share (vs UK£0.061 loss in FY 2022)

Redx Pharma Plc to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Financial data availability

Redx Pharma plc to Present Preclinical Data on RXC009, A Selective Discoidin Domain Receptor 1 Inhibitor

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £14.059359 million.

Redx Pharma plc Appoints Joseph Anderson as Non-Executive Director

Redx Pharma Plc Announces Executive Changes

Redx Pharma plc Zelasudil Receives FDA Orphan Drug Designation

New minor risk - Market cap size

Redx Pharma Plc Announces Directorate Changes

First half 2023 earnings released: UK£0.062 loss per share (vs UK£0.035 loss in 1H 2022)

Redx Pharma Plc's Discovery of Pirtobrutinib Recognised with Unveiling of Commemorative Plaque At Alderley Park

Redx Pharma Plc Presents Preclinical Efficacy Data for RXC007 Showing Significant Results in Cancer-Associated Fibrosis Models

Redx Pharma Plc to Report First Half, 2023 Results on May 17, 2023

Full year 2022 earnings released: UK£0.061 loss per share (vs UK£0.084 loss in FY 2021)

Redx Pharma Plc, Annual General Meeting, Mar 14, 2023

Redx Pharma Plc Provides Progress Updates on RXC007 Clinical Programme

Full year 2022 earnings released: UK£0.061 loss per share (vs UK£0.084 loss in FY 2021)

Redx Pharma Plc to Report Q4, 2022 Results on Dec 20, 2022

High number of new directors

Redx Pharma plc to Present on Potential of RXC007 in Fibrotic Diseases at Antifibrotic Drug Discovery Meeting

Redx Pharma plc Announces First Patient Dosed in Phase 2a Trial for RXC007

Redx Pharma Announces Two Presentations Were Delivered at the Inaugural Extracellular Matrix Pharmacology Congress in Copenhagen, 23-25 June

First half 2022 earnings released

Redx Pharma Plc to Report Q2, 2022 Results on Jun 23, 2022

Redx Pharma Plc has completed a Follow-on Equity Offering in the amount of £34.261864 million.

High number of new directors

Redx Pharma Plc Presents Encouraging RXC004 Preclinical Data

Redx Pharma plc Announces Nomination of Clinical Development Candidate

Redx Pharma Plc Announces Committee Changes

Redx Pharma Plc, Annual General Meeting, Mar 08, 2022

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

First half 2021 earnings released: UK£0.053 loss per share (vs UK£0.027 loss in 1H 2020)

Non-Executive Chairman Iain Ross has left the company

Redx Pharma Announces First Subject Dosed in Phase 1 Study with Lead Fibrosis Candidate RXC007, a ROCK2 Selective Inhibitor

Redx Pharma Announce Mead Will Step Down from the Board

Redx Pharma plc Announces Search for A US Based Chief Financial Officer Has Been Initiated

Chief Medical Officer has left the company

Redx Pharma Plc, Annual General Meeting, Mar 02, 2021

Full year 2020 earnings released

Revenue misses expectations

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin